Abstract
When pediatric, adolescent, and young adult patients present with a bone sarcoma, treatment decisions, especially after relapse, are complex and require a multidisciplinary approach. This review presents scenarios commonly encountered in the therapy of bone sarcomas with the goal of objectively presenting a consensus, multidisciplinary management approach. Little variation was found in the authors' group with respect to local control or systemic therapy. Clinical trials were universally prioritized in all settings. Decisions regarding relapse therapies in the absence of a clinical trial had very minor variations initially, but a consensus was reached after a literature review and discussion. This review presents a concise document and figures as a starting point for evidence-based care for patients with these rare diseases. This framework allows prospective decision making and prioritization of clinical trials. It is hoped that this framework will inspire and focus future clinical research and thus lead to new trials to improve efficacy and reduce toxicity. Cancer 2017;123:2206–2218.
Original language | English (US) |
---|---|
Pages (from-to) | 2206-2218 |
Number of pages | 13 |
Journal | Cancer |
Volume | 123 |
Issue number | 12 |
DOIs | |
State | Published - Jun 15 2017 |
Keywords
- Ewing sarcoma
- adolescent and young adult (AYA)
- chemotherapy
- osteosarcoma
- pathways
- pediatric
ASJC Scopus subject areas
- Oncology
- Cancer Research